Holen Sie sich die Stockscreener-App
1.13
0.89%
0.010
Vorhandelsmarkt:
1.09
-0.04
-3.54%
Opus Genetics Inc Aktie (IRD) Neueste Nachrichten
Opus Genetics (NASDAQ:IRD) Raised to “Hold” at Wall Street Zen - Defense World
Opus Genetics, Inc.'s (NASDAQ:IRD) Price Is Right But Growth Is Lacking - simplywall.st
Opus Genetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Opus Genetics Reveals Major Equity Package: 240K Options, 150K RSUs for Key Gene Therapy Talent - Stock Titan
In Brief: Opus Gears Up For FDA Filing In Presbyopia - insights.citeline.com
Opus Genetics' VEGA-3 presbyopia trial meets endpoints for phentolamine 0.75% - Eyes On Eyecare
Processa hands cancer candidate back to Opus Genetics after deciding milestone out of reach - Fierce Biotech
Retinal Degeneration Fund providing funding to Opus Genetics to support OPGx-MERTK program - Ophthalmology Times
Opus Genetics (NASDAQ:IRD) Given “Buy” Rating at HC Wainwright - Defense World
Biotech's treatment shows promise for age-related vision loss - The Business Journals
OCUP SEC FilingsOcuphire Pharma Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Opus Genetics Announces VEGA-3 Phase 3 Trial Met its - GlobeNewswire
Viatris Eye Drops Data Shows Promise For Blurred Near Vision - Benzinga
Opus Genetics (IRD) Secures $2M Funding for Gene Therapy Development | IRD Stock News - GuruFocus
Opus Genetics Awarded Non-Dilutive Funding from the RD Fund to Support Preclinical Development of OPGx-MERTK Program - The Manila Times
Opus Genetics Secures Funding for MERTK Program - TipRanks
Opus Genetics (IRD) Receives "Buy" Rating from Lucid Capital Markets | IRD Stock News - GuruFocus
Opus Genetics (IRD) Receives "Buy" Rating from Lucid Capital Mar - GuruFocus
Opus Genetics (IRD) Receives Buy Rating Amid Promising Trial Res - GuruFocus
Opus Genetics, Inc.Common Stock (Nasdaq:IRD) Stock Quote - FinancialContent
Opus Genetics (IRD) Achieves Success in Phase 3 Trial for Night Driving Vision Treatment | IRD Stock News - GuruFocus
Opus Genetics reports success in night vision trial - Investing.com
Opus Genetics reports success in night vision trial By Investing.com - Investing.com UK
Opus Genetics Announces LYNX-2 Phase 3 Trial Met its - GlobeNewswire
Opus Genetics Announces LYNX-2 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients with Visual Disturbances Under Mesopic, Low-Contrast Conditions - GlobeNewswire Inc.
Why is Opus Genetics Inc. Rising? - timothysykes.com
Analysts Are Upgrading Opus Genetics, Inc. (NASDAQ:IRD) After Its Latest Results - simplywall.st
Opus Genetics, Inc. (NASDAQ:IRD) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates - Yahoo Finance
Opus Genetics: Can Revenue Momentum Overcome Losses and Unlock Value? - AInvest
Opus Genetics, Inc. (IRD) Reports Q1 Loss, Tops Revenue Estimates - MSN
Opus Genetics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Opus Genetics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Opus Genetics Announces Financial Results for First Quarter 2025 and Provides Corporate Update - GlobeNewswire
IRD Reports Strong Q1 Revenue Growth and Encouraging Trial Data - GuruFocus
Opus Genetics Inc (IRD) Q1 2025 Earnings: EPS of $(0.24) Beats E - GuruFocus
IRD Reports Strong Q1 Revenue Growth and Encouraging Trial Data | IRD Stock News - GuruFocus
Opus Genetics Q1 2025 Financial Results and Corporate Update - TradingView
Opus Gene Therapy Shows 12-Month Vision Restoration Success, Gains FDA RMAT Status | IRD Stock News - Stock Titan
Opus Genetics (IRD) Showcases Advances in Gene Therapy at May Co - GuruFocus
Opus Genetics (IRD) Showcases Advances in Gene Therapy at May Conferences | IRD Stock News - GuruFocus
Opus Genetics to Present Advances in Gene Therapy for Inherited Retinal Diseases at Major Scientific Conferences in May 2025 - Nasdaq
Opus Genetics Announces Presentations on Inherited Retinal Disease Programs at Medical Conferences in May - GlobeNewswire
FDA grants RMAT status to Opus Genetics’ OPGx-LCA5 gene therapy - Yahoo Finance
Opus Genetics (IRD) Secures RMAT Status for Gene Therapy OPGx-LC - GuruFocus
Opus Genetics (IRD) Secures RMAT Status for Gene Therapy OPGx-LCA5 | IRD Stock News - GuruFocus
FDA grants Opus Genetics RMAT status for eye therapy - Investing.com
Opus Genetics Granted FDA Regenerative Medicine Advanced - GlobeNewswire
Opus Genetics Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for OPGx-LCA5 Gene Therapy Candidate - The Manila Times
FDA grants Opus Genetics RMAT status for eye therapy By Investing.com - Investing.com South Africa
FDA Fast-Tracks Revolutionary Gene Therapy for Ultra-Rare Inherited Blindness Treatment - Stock Titan
Opus Genetics (IRD) Reveals Promising Gene Therapy Trial Results | IRD Stock News - GuruFocus
Opus Genetics Announces Presentation of OPGX-LCA5 Gene Therapy Data at ARVO; 12 Month Phase 1/2 Results Support Potential to Restore to Meaningful Vision - The Manila Times
Opus Genetics Announces Presentation of OPGX-LCA5 Gene - GlobeNewswire
Gene Therapy Breakthrough: Opus Reports 3.5-Line Vision Improvement After 1 Year in Rare Eye Disease Trial - Stock Titan
IRDOpus Genetics Latest Stock News & Market Updates - Stock Titan
2.10%
1.57%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):